Autolus Therapeutics (NASDAQ:AUTL) Posts Earnings Results, Beats Expectations By $0.12 EPS

Autolus Therapeutics (NASDAQ:AUTL) released its earnings results on Thursday. The company reported ($0.09) EPS for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.12, Zacks reports. The business had revenue of $0.03 million for the quarter, compared to the consensus estimate of $2.98 million.

Autolus Therapeutics Trading Up 1.5 %

Shares of NASDAQ AUTL opened at $1.70 on Friday. Autolus Therapeutics has a 12 month low of $1.56 and a 12 month high of $6.60. The firm has a market capitalization of $452.36 million, a price-to-earnings ratio of -1.40 and a beta of 2.07. The business has a 50-day moving average of $2.02 and a 200-day moving average of $2.92.

Analyst Upgrades and Downgrades

AUTL has been the topic of a number of research reports. Needham & Company LLC restated a “buy” rating and issued a $10.00 price objective on shares of Autolus Therapeutics in a research note on Monday, January 13th. Wells Fargo & Company reduced their target price on Autolus Therapeutics from $8.00 to $6.00 and set an “overweight” rating for the company in a report on Friday. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $9.52.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.